Atlas Trials

Neurogenic Detrusor Overactivity

22 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Neurogenic Detrusor Overactivity

RecordFirmDate
Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer (NCT04452838)Pfizer2020-06-26
BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG (NCT04478357)Pfizer2019-11-12
Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury (NCT03482037)RECORDATI GROUP2018-06-07
Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury (NCT03168828)Taris Biomedical LLC2017-04-24
Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NCT02751931)Astellas Pharma Europe B.V.2016-06-17
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB) (NCT02526979)Astellas Pharma Europe B.V.2015-12-17
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder (NCT02211846)Astellas Pharma Inc2014-09-21
Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury? (NCT02138149)Swiss Paraplegic Research, Nottwil2013-11-01
A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) (NCT01981954)Astellas Pharma Europe B.V.2013-09-25
A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity (NCT01565694)Astellas Pharma Europe B.V.2012-08-14
Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder (NCT01539707)Astellas Pharma Inc2012-03-13
Treatment of Neurogenic Detrusor Overactivity: Early Versus Late Pudendal Nerve Stimulation in Spinal Cord Injury (SCI) Patients (NCT01043848)Ulrich Mehnert2009-12-01
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years (NCT00857896)Pfizer2009-03-01
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity (NCT00712322)Warner Chilcott2008-10-07
Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity (NCT00800462)Toronto Rehabilitation Institute2008-03-01
Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity (NCT01091727)Sunnybrook Health Sciences Centre2006-10-01

Track Neurogenic Detrusor Overactivity automatically

Every clearance here is in the API, with alerts when new ones post.